Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/4439
A61K-031/404
C07D-401/06
C07D-209/08
출원번호
UP-0189709
(2008-08-11)
등록번호
US-7786146
(2010-09-20)
발명자
/ 주소
Vernier, Jean-Michel
Chen, Huanming
Song, Jianlan
출원인 / 주소
Valeant Pharmaceuticals International
대리인 / 주소
McDermott Will & Emery LLP
인용정보
피인용 횟수 :
3인용 특허 :
32
초록▼
This invention provides compounds of formula I where the dashed line represents an optional double bond; where R1 is phenyl, naphthyl, pyridyl, pyrimidyl, pyrrolyl, imidazolyl, pyrazyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, optionally substituted, and other substitue
This invention provides compounds of formula I where the dashed line represents an optional double bond; where R1 is phenyl, naphthyl, pyridyl, pyrimidyl, pyrrolyl, imidazolyl, pyrazyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, optionally substituted, and other substituents are defined herein. Such compounds are potassium channel modulators.
대표청구항▼
What is claimed is: 1. A compound which is one of the following: N-[1-(4-Trifluoromethylbenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide N-[1-(4-Fluorobenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide N-[1-(3-Chlorobenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide N-[1-(
What is claimed is: 1. A compound which is one of the following: N-[1-(4-Trifluoromethylbenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide N-[1-(4-Fluorobenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide N-[1-(3-Chlorobenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide N-[1-(4-Bromobenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide N-[1-(3,4-Difluorobenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide N-(4,6-Dimethyl-1-(naphthalen-2-ylmethyl)indolin-5-yl)-3,3-dimethylbutanamide N-(4,6-Dimethyl-1-(pyridin-4-ylmethyl)indolin-5-yl)-3,3-dimethylbutanamide N-(4,6-Dimethyl-1-(pyridin-3-ylmethyl)indolin-5-yl)-3,3-dimethylbutanamide N-(4,6-Dimethyl-1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)-3,3-dimethyl butanamide N-(4,6-Dimethyl-1-(4-(fluorobenzyl)-1H-indol-5-yl)-3,3-dimethylbutanamide N-(4,6-Dimethyl-1-(3,4-difluorobenzyl)-1H-indol-5-yl)-3,3-dimethylbutanamide N-(4,6-Dimethyl-1-(3,5-difluorobenzyl)-1H-indol-5-yl)-3,3-dimethylbutanamide N-(4,6-Dimethyl-1-(3-chlorobenzyl)-1H-indol-5-yl)-3,3-dimethylbutanamide and N-(4,6-Dimethyl-1-(4-bromobenzyl)-1H-indol-5-yl)-3,3-dimethylbutanamide. 2. The compound of claim 1 that is N-[1-(4-Trifluoromethylbenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide. 3. The compound of claim 1 that is N-[1-(4-Fluorobenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide. 4. The compound of claim 1 that is N-[1-(3-Chlorobenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide. 5. The compound of claim 1 that is N-[1-(4-Bromobenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide. 6. The compound of claim 1 that is N-[1-(3,4-Difluorobenzyl)-4,6-dimethylindoline-5-yl]-3,3-dimethyl-butyramide. 7. The compound of claim 1 that is N-(4,6-Dimethyl-1-(naphthalen-2-ylmethyl)indolin-5-yl)-3,3-dimethylbutanamide. 8. The compound of claim 1 that is N-(4,6-Dimethyl-1-(pyridin-4-ylmethyl)indolin-5-yl)-3,3-dimethylbutanamide. 9. The compound of claim 1 that is N-(4,6-Dimethyl-1-(pyridin-3-ylmethyl)indolin-5-yl)-3,3-dimethylbutanamide. 10. The compound of claim 1 that is N-(4,6-Dimethyl-1-(4-(trifluoromethyl)benzyl)-1H-indol-5-yl)-3,3-dimethyl butanamide. 11. The compound of claim 1 that is N-(4,6-Dimethyl-1-(4-(fluorobenzyl)-1H-indol-5-yl)-3,3-dimethylbutanamide. 12. The compound of claim 1 that is N-(4,6-Dimethyl-1-(3,4-difluorobenzyl)-1H-indol-5-yl)-3,3-dimethylbutanamide. 13. The compound of claim 1 that is N-(4,6-Dimethyl-1-(3,5-difluorobenzyl)-1H-indol-5-yl)-3,3-dimethylbutanamide. 14. The compound of claim 1 that is N-(4,6-Dimethyl-1-(3-chlorobenzyl)-1H-indol-5-yl)-3,3-dimethylbutanamide. 15. The compound of claim 1 that is N-(4,6-Dimethyl-1-(4-bromobenzyl)-1H-indol-5-yl)-3,3-dimethylbutanamide.
Piyasena Hewawasam ; Pierre Dextraze CA; Valentin K. Gribkoff ; Gene G. Kinney ; Steven I. Dworetzky, Fluoro oxindole derivatives as modulators if KCNQ potassium channels.
Aberg A. K. Gunnar (Lawrenceville NJ) Ogletree Martin L. (Newtown PA) O\Keefe Eugene H. (Newtown PA), Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activato.
Dieter Hans-Reinhold (Darmstadt DEX) Engel Jurgen (Alzenau DEX) Kutscher Bernhard (Maintal DEX) Polymeropoulos Emanuel (Frankfurt DEX) Szelenyi Stefan (Schwaig DEX) Nickel Bernd (Muhltal DEX), Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes for their preparation and pharmaceutical compositi.
Carroll, William A.; Chen, Yiyuan; Holladay, Mark W.; Kort, Michael E.; Kym, Philip R.; Sullivan, James P.; Tang, Rui; Yi, Lin; Zhang, Henry Q.; Drizin, Irene, Potassium channel openers.
Rostock Angelika,DEX ; Rundfeldt Chris,DEX ; Tober Christine,DEX ; Bartsch Reni,DEX, Use of 2-4-amino-4-(4-fluorobenzylamino) (-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of the neurod.
Rostock Angelika,DEX ; Rundfeldt Chris,DEX ; Tober Christine,DEX ; Bartsch Reni,DEX, Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of reduced cerebr.
Rundfeldt Chris,DEX ; Bartsch Reni,DEX ; Rostock Angelika,DEX ; Tober Christine,DEX ; Dost Rita,DEX, Use of retigabine for the treatment of neuropathic pain.
Rundfeldt,Chris; Kuss,Hildegard; Draheim,Regina; Bernoester,Katrin, Use of the non-opiate analgesic drug flupirtine for the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowel syndrome.
Demopulos Gregory A. ; Pierce Pamela A. ; Herz Jeffrey M., Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.